膀胱癌多药耐药性的检测及其意义  

Detecting multi-drug resistance of bladder cancer for the intravesical chemotherapy

作　　者：康新立[1] 耿振宏[2] 鲁兴湘[2] 魏超[2] 王金刚[1] 王三忠[1] 马森[1] 刘洪新[1] 徐国营[1] 张华巍[1] 王国勇[1] 

机构地区：[1]中国石化集团胜利医院泌尿外科,山东省东营市257055 [2]中国石化集团胜利医院病理科,山东省东营市257055

出　　处：《中华外科杂志》2004年第5期285-287,共3页Chinese Journal of Surgery

摘　　要：目的　探讨膀胱癌的多药耐药性 (MDR)以指导灌注化疗用药。　方法　采用免疫组化法检测 4 4例膀胱癌病理标本 ,分析P 糖蛋白 (P gp)、谷胱甘肽S转移酶 (GST π)和拓扑异构酶 (TOPO Ⅱ )的表达情况。　结果　 5 4 5 %的病例P gp高表达 ;6 5 9%的病例GST π无表达和低表达 ;TOPO Ⅱ ,高表达 2 9 5 % ,而低表达 6 5 9%。　结论　检测膀胱癌MDR可指导灌注化疗用药。Objective To explore multi-drug resistance (MDR) of bladder cancer for the intravesical instillation. Methods Using immunohistochemical staining,in 44-case human bladder cancer cells, the expressions of P-glyprotein (P-gp),glutathione S-transferase (GST-π) and topoisomerase (TOPO-Ⅱ),were detected to find out the resistance to drugs. Results P-gp had a higher expression in 54.5% cases. GST-π had no or a lower expression in 65.9% cases. TOPO-Ⅱ had a higher expression in 29.5% but a lower expression in 65.9% cases. Conclusion Detecting the factors of MDR in bladder cancer cells could help to choose drugs for intravesical chemotherapy.

关 键 词：膀胱癌 多药耐药性 检测 治疗 

分 类 号：R737.14[医药卫生—肿瘤]